Fred D. Lublin, MD, discusses evolving concepts in MS, including earlier high-efficacy therapy, unrecognized progression, and ...

Multiple sclerosis (MS) is a condition that disrupts the information pathways that connect your brain and your body. From time to time, the symptoms of MS can unexpectedly worsen. When symptoms ...

Briumvi significantly outperformed Aubagio at reducing disease activity in people with highly active relapsing forms of MS, a ...

In relapse-remitting multiple sclerosis (MS), people experience periods of high MS activity where they have more symptoms or imaging tests show inflammation. Between these periods, the condition might ...

A second clinical trial testing fenebrutinib for MS has met its main goal, once again beating approved Aubagio in reducing ...

Disability progression independent of relapse activity (PIRA) -- sometimes referred to as silent progression -- is a key integrating concept in the contemporary view of multiple sclerosis (MS). "The ...

Kesimpta is a medicine used to treat relapsing forms of multiple sclerosis (MS). Relapsing forms of MS include clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS ...

Rituximab (Rituxan) provides consistently better relapse outcomes than natalizumab (Tysabri) in patients with multiple sclerosis (MS), new research suggests. Findings from a real-world "comparative ...

October 12, 2012 (Lyon, France) — Final results of a phase 3 trial comparing 2 doses of teriflunomide (Aubagio, Genzyme/Sanofi), 14 mg/d and 7 mg/d, vs placebo in patients with relapsing multiple ...

If you click on links we provide, we may receive compensation. "I haven't spent enough time having dreams. And now it's like, what are my dreams?" Blair tells PEOPLE Abby Stern is a writer-reporter at ...

Multiple sclerosis (MS) is a chronic autoimmune, neurodegenerative disease that attacks the central nervous system (CNS). These attacks lead to the breakdown of myelin, the protective cover that ...